Funding Announcements

"We’re overwhelmed by the interest we’ve received. It’s incredible to see the passion and confidence we have in Nscale is matched by key investors. "

"We are building the AI-native Infrastructure platform of tomorrow. AI is reshaping industries, economies, and national strategies – but it cannot happen without the physical backbone: the data centres, the GPUs and the software to orchestrate them. We are building a vertically integrated, AI-engineered foundation designed to power the next generation of technological change, enabling industries and innovators across the globe to achieve what today feels impossible."

"In enterprise AI, capability means nothing without context. The agents that will win are the ones that understand the work – that’s what we make possible. Our technology shows companies where AI can make the biggest impact and gives agents the process knowledge to deliver it. Our goal is to help the world’s biggest organizations move AI from an interesting internal experiment to something that runs at the heart of the business and takes on the burden and mundanity of repetitive tasks, so employees can spend their time more wisely."

"We’re actively creating quantum advantage at Phasecraft. Our algorithms are delivering meaningful results now, whether it’s simulating the physics of complex materials or optimizing the structure of a large energy network, whilst our partnerships with the world’s top quantum hardware providers increase the impact our algorithms will have for commercial applications. We’re delighted to have the backing of our visionary investors such as Plural, Playground Global, and Novo Holdings, to support us on the mission to bring quantum advantage to the world faster."

"This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier. This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio."